source
- AstraZeneca’s newly approved pill fails frontline breast cancer studyEtcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
- Abbott to pay $385 million to settle claims over 2022 baby-formula plant shutdownAbbott Laboratories agreed to a $385 million settlement related to the 2022 shutdown of its Sturgis, Michigan baby-formula plant, the largest in the United States. The plant’s problems triggered a…